<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00261079</url>
  </required_header>
  <id_info>
    <org_study_id>M016455_4125</org_study_id>
    <nct_id>NCT00261079</nct_id>
  </id_info>
  <brief_title>Fexofenadine in Pruritic Skin Disease</brief_title>
  <official_title>The Evaluation of Efficacy and Safety of Fexofenadine 180mg Tablets for 7 Days in the Treatment of Pruritic Skin Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Handok Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Handok Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:&#xD;
&#xD;
        -  To compare the efficacy and safety profile of Fexofenadine 180mg tablets plus&#xD;
           prednicarbate(2.5mg/g) vs prednicarbate(2.5mg/g) alone in the treatment of pruritic skin&#xD;
           disease&#xD;
&#xD;
      Secondary objective:&#xD;
&#xD;
        -  To evaluate patient's satisfaction of Allegra treatment&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of physician's assessment on pruritic score before and after 7-day treatment.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient visual analogue scale change and Overall satisfaction.</measure>
  </secondary_outcome>
  <enrollment type="Actual">435</enrollment>
  <condition>Pruritus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fexofenadine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        The following information on clinical trials is provided for information purposes only to&#xD;
        allow patients and physicians to have an initial discussion about the trial. This&#xD;
        information is not intended to be complete information about the trial, to contain all&#xD;
        considerations that may be relevant to potential participation in the trial, or to replace&#xD;
        the advice of a personal physician or health professional.&#xD;
&#xD;
        Main criteria are listed hereafter:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients diagnosed with atopic dermatitis, contact dermatitis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other skin disease except atopic dermatitis, contact dermatitis.&#xD;
&#xD;
          -  Subjects taken steroid within 4 weeks and antihistamine within 1 week before screening&#xD;
             day.&#xD;
&#xD;
          -  Pruritus localized only head and face&#xD;
&#xD;
          -  Subjects with severe hepatic, renal, heart dysfunction.&#xD;
&#xD;
          -  Subjects with history of alcohol and drug abuse.&#xD;
&#xD;
          -  Pregnant and lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyou-Young Rhim, MD</last_name>
    <role>Study Director</role>
    <affiliation>Handok Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Handok</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <study_first_submitted>December 1, 2005</study_first_submitted>
  <study_first_submitted_qc>December 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2005</study_first_posted>
  <last_update_submitted>November 5, 2007</last_update_submitted>
  <last_update_submitted_qc>November 5, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pruritus</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fexofenadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

